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ABSTRACT: 
 
  
 Since the development of combination antiretroviral therapy, morbidity and 
mortality due to AIDS-related malignancies has declined significantly. In most patients, 
daily administration of a multidrug antiretroviral regimen is sufficient to suppress viral 
replication and reduce immune activation and inflammation. In spite of this, residual 
viremia persists for many years in the vast majority of patients, and immune activation 
remains higher than pre-infection baseline. Chronic immune activation and inflammation 
are associated with a variety of adverse health consequences including higher risks of 
cancer, heart disease, liver, and kidney problems. Moreover, these risks are not 
normalized to those of healthy individuals when patients are on long-term antiretroviral 
therapy. 
 
 Due to the deleterious effects of chronic inflammation, it is desirable to develop 
treatments aimed at reducing immune activation in patients on suppressive antiretroviral 
therapy. Unfortunately, the variables that drive chronic inflammation are unclear, but 
could result from multiple factors including antigenic stimulation via residual viremia, 
microbial translocation from the gut into the blood due to damage of the gastrointestinal 
tract, and a reduction in the ability of the immune system to mount rapid immune 
responses against commonly encountered pathogens. In order to better control chronic 
immune activation, the variables that influence it must first be determined. 
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 In this thesis, I report on two studies of residual viremia in the context of immune 
activation. The first is a report of virologic data derived from a clinical trial of patients 
with sub-optimal reconstitution of the CD4+ T cell compartment. The second is a study 
regarding the relationship between immune activation, residual viremia, and CD4+ T cell 
count in the context of regulatory T cells. Neither study found a correlation between 
immune activation and residual viremia, indicating that immune activation may not be 
not driven by continuous antigenic stimulation provided by persistent virion production. 
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CHAPTER 1: HISTORY OF HIV-1 INFECTION 
 
 
 
 
1.1 – HISTORY AND IDENTIFICATION OF HIV-1 
 
 
 In the summer of 1981, a clinical study published in the New England Journal of 
Medicine reported an alarmingly high incidence of Pneumocystis jirovecii in a population 
of gay men in San Francisco1. These men presented with acute lymphoadenopathy, 
suggesting some form of systemic infection. Although immunocompromised individuals 
were known to be susceptible to this pathogen, these men had no obvious reasons for 
which they should be immunocompromised. It was hypothesized in this report that some 
known pathogen, such as cytomegalovirus, could be the etiological agent driving P. 
jirovecii infections. 
 
 As the number of cases of immunocompromised gay men grew, a search began 
for the causative agent of this syndrome. The first instance in which this “acquired 
immunodeficiency syndrome” (AIDS) could be caused by a retrovirus came in 1983 
from the work of Francoise Barré-Sinoussi at the Pasteur Institute in France, who 
discovered a virus containing reverse transcriptase activity from the lymph node from a 
man with persistent lymphadenopathy2. However, since lymphadenopathy is common in 
a variety of viral infections, there was still debate in the medical community regarding 
whether AIDS was caused by a known human pathogen. This debate was further 
bolstered by two publications in Science describing the detection and isolation of human 
T cell leukemia virus (HTLV) from patients with AIDS3,4. However, HTLV was known to 
have a close association with lymphocytes5, which the virus could transform but did not 
kill these cells5. These factors were at odds with reports describing transmission of 
AIDS to hemophiliacs receiving cell-free plasma products6, as well as the marked loss 
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of CD4+ T lymphocytes that became a defining characteristic of AIDS pathogenesis1. 
Clearly, more work was required to resolve these discrepancies. 
 
 As Barré-Sinoussi continued her work, she discovered that the virus she isolated, 
which she named lymphadenopathy-associated virus (LAV) infected and killed CD4+ T 
lymphocytes in cell culture7. In the United States, work by Robert Gallo identified a virus 
in AIDS patients that demonstrated cross-reactivity with HTLV8. Gallo therefore included 
his virus in the HLTV family, naming it HLTV-III9. Shortly thereafter, LAV and HTLV-III 
were recognized as the primary isolates of the same human retrovirus10,11, which 
differed considerably from other known human retrovirus12. Due to these revelations, 
the AIDS virus was given a unique name: the human immunodeficiency virus, or HIV13. 
 
 
 
 
1.2 – DEVELOPMENT AND CURRENT STATE OF COMBINATION 
ANTIRETROVIRAL THERAPY 
 
 
 Following the identification of HIV, it became apparent that most infected 
individuals remained asymptomatic for many years before showing symptoms. Indeed, 
the median asymptomatic period between infection and AIDS defining illnesses is 
approximately 10 years14. Despite this, the range of the asymptomatic period varies 
considerably among infected individuals. In rare circumstances, individuals were unable 
to mount an effective immune response against the virus and died during the primary 
infection. In other rare cases, infected individuals remained asymptomatic indefinitely 
and were labeled “long-term non-progressors.15-17” As the virus spread through the 
homosexual community and later, heterosexual individuals, the need for drugs to treat 
or cure the infection became a priority. This lead to the development of numerous drugs 
aimed at suppressing viral replication, thereby reducing viral load and CD4+ T 
lymphocyte destruction. 
 
 The first drug developed to treat HIV infection was zidovudine (AZT), a 
nucleoside-reverse transcriptase inhibitor (NRTI). Initially developed as a cancer drug, it 
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was discovered that AZT blocked the activity of reverse transcriptase, effectively 
shutting down the conversion of HIV single stranded RNA to double stranded DNA18. 
Although effective, AZT also blocked cellular & mitochondrial polymerases at high 
clinical doses and caused severe side effects19. Furthermore, AZT could only suppress 
viral replication transiently before mutations in reverse transcriptase rendered the drug 
ineffective20-22. Throughout the early- and mid-1990’s, additional NRTIs were 
developed23-26, as were several drugs that blocked reverse transcriptase at an allosteric 
site, now known as the non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
nevirapine27, delavirdine28, and efavirenz29. When used in combination, these drugs 
could be used at lower doses to reduce side effects, and were effective at maintaining 
viral suppression, especially in the context of drug resistant mutations30. Unfortunately, 
virus suppression was incomplete and patients still progressed to AIDS due to drug 
resistant mutants that emerged after weeks to months of dual therapy31-33. 
 
 The development of protease inhibitors (PIs) in the mid-1990’s was the 
breakthrough required to achieve durable control of HIV34. It was shown that when PIs 
were used in combination with NRTIs and NNRTIs, viral suppression could be 
maintained almost indefinitely35, given that no previous drug resistant mutations existed 
and patients adhered to their drug regimens. Since then, viral entry inhibitors36,37, 
integrase inhibitors38,39, and second generation NNRTIs and PIs have also been 
developed. At present, a variety of combination therapies have been validated in clinical 
trials (discussed in Chapter 3.3), and a number of drugs are available for salvage 
regimens when first line therapies fail. 
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CHAPTER 2 – BIOLOGY OF HIV INFECTION 
 
 
 
 
2.1 – TRANSMISSION OF HIV 
 
 
 HIV can be transmitted through three primary routes: (1) unprotected sexual 
intercourse1,40-42, (2) intravenous drug use with contaminated needles40, and (3) mother-
to-child transmission during birth43,44. Although there have been reports of individuals 
contracting HIV through blood transfusions6, modern serum surveillance practices have 
rendered this method of transmission less common. Although intravenous drug use and 
mother-to-child transmission are significant methods of transmission, the focus herein 
will be on unprotected sexual intercourse. 
 
 Factors associated with a high risk of HIV infection are well established. 
Unprotected sex with multiple partners is the most predominant risk factor45, as 
individuals who engage in these activities are at high risk of encountering HIV. The risk 
of transmission is higher during acute infection46 or when the infected partner has 
sexually transmitted diseases other than HIV47-49, which results in recruitment of 
activated CD4+ T lymphocytes to the site of infection. Considering the manner of sex 
involved, the risk is highest in those who engage in receptive anal intercourse45; this 
activity often damages the rectal mucosa, giving the HIV found in semen access to the 
immune cells underlying the endothelial layers of the gastrointestinal tract. Unprotected 
insertive anal intercourse50 and vaginal intercourse42 can also transmit HIV, either 
through the urethral lining of the penis or the vagina mucosa respectively. 
 
 Once HIV gains access to the intestinal mucosal lining, free virus or cell-
associated virus translocates from the apical surface of the epithelial lining to sub-
mucosal sites via resident M cells51. Here, the virus infects immune cells in lymph node-
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like structures known as Peyer’s patches located in the gastrointestinal tract. 
Replication is slow during the first few days of infection as the virus reproduces in 
Langerhan’s cells, resident macrophages, activated, and resting T cells52,53. Within two 
days, virus disseminates from the initial site of infection to draining lymph node, and 
viremia develops within 5-7 days52,53. At this time, the virus begins to replicate in 
secondary lymphoid organs and establishes long-lived cellular reservoirs54, which 
become critically important in eradication of HIV during long-term suppressive 
combination ART. 
 
 
 
 
2.2 – ESTABLISHMENT OF LONG-LIVED CELLULAR RESERVOIRS 
 
 
 Due to a number of factors, HIV preferentially infects activated CD4+ T 
lymphocytes. These include, (1) up-regulation of the HIV co-receptor, CCR5, during T 
lymphocyte activation55,56, (2) an increase in deoxynucleotide triphosphates, which are 
required for reverse transcription and are rare in resting T lymphocytes, and (3) the 
availability of transcription factors that are indispensible to HIV transcription, which are 
synthesized only upon cellular activation. Considering these requirements, latent 
infection is believed to occur when HIV infects an activated T cell, but the viral lifecycle 
stalls following integration of the HIV provirus. This is thought to occur when HIV infects 
an activated cell that is reverting to a resting state. In the context of untreated HIV 
infection, these events have little clinical meaning; productive infections produce virions 
and drive HIV pathology, and the rare, transcriptionally silent proviruses are of little 
pathological consequence. However, upon initiation of cART, productively infected cells 
are quickly cleared and new rounds of infection prevented35,57,58, such that only cells 
harboring quiescent proviruses remain. The vast majority of infected cells contain 
replication-deficient proviruses and are clinically irrelevant59. However, a small subset 
consisting of approximately one million infected cells harbor replication-competent 
provirus that sporadically activate, producing infectious virus capable of reinitiate the 
viral lifecycle in the absence of antiretroviral therapy59. These cells were identified by 
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three groups as circulating, resting CD4+ T lymphocytes60-62, and further work has 
shown they have a memory phenotype63,64. It is these cells, which were infected prior to 
the initiation of cART, that represent long-lived cellular reservoirs of HIV and preclude 
eradication of HIV by cART alone. 
 
 In addition to circulating CD4+ T lymphocytes, a number of anatomical sites have 
been identified as possible long-lived reservoirs of HIV. The first is the gastrointestinal 
tract, which harbors up to 70% of the body’s immune cells65. CD4+ T cells in this 
location express higher levels of CCR5 than in the periphery, rendering them more 
susceptible to HIV infection. Indeed, during primary infection, a significant fraction of 
CD4+ CCR5+ T cells in the gut are eradicated66, and this population fails to recover, 
even during long-term cART67. Although a critical site of interest, the infection in the 
gastrointestinal tract is difficult to study since the number of CD4+ T lymphocytes 
recoverable by biopsies is extremely limited. 
 
 The bone marrow and central nervous system are two other anatomical sites of 
interest and are similarly limited in the number of recoverable CD4+ T lymphocytes. A 
number of recent studies have examined the role of bone marrow-derived cells, 
particularly CD34+ hematopoietic stem cells, as reservoirs of HIV. Initial in vitro studies 
indicated that CD34+ cells were susceptible to HIV infection68, and a recent study 
detected the presence of HIV DNA in CD34+ cells isolated from patients on suppressive 
cART69. Unfortunately, the purity of CD34+ cells in this study was sub-optimal, and a 
more recent report examining highly pure CD34+ cells in a similar cohort failed to detect 
HIV DNA70. These differences may also be due to viral tropism, as CD34+ T cells are 
susceptible to CXCR4 tropic viruses (but not CCR5 tropic viruses), which often arise 
during prolonged chronic infection as patients progress to AIDS.  
 
 The central nervous system is particularly difficult to study since tissue from the 
brain and spinal cord are difficult to obtain in living patients. However, it is known that 
the viral titer in cerebral spinal fluid decreases dramatically during cART71, despite the 
fact that a number of cART drugs disseminate poorly into the central nervous system72. 
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It has also been established that resident macrophages of the brain, termed microglia, 
can be infected by HIV73. Furthermore, HIV-related neuropathies occur in patients on 
cART74. Whether this is due to the CNS acting as a long-lived reservoir of HIV, or is a 
side effect from systemic issues such as chronic immune activation, has yet to be 
determined. 
 
 
 
 
2.3 – IMMUNE ACTIVATION OF HIV INFECTION 
 
 
 The immune system responds to HIV infection first through innate immune 
responses, followed by an adaptive response via HIV-specific CD4+ and CD8+ T 
lymphocytes. The activation of HIV-specific CD4+ T lymphocytes can be viewed as a 
double-edged sword. On the one hand, these cells help orchestrate the adaptive 
immune response against the virus. On the other, activation of these cells provides ideal 
sites of replication for the virus. In any case, the adaptive immune response is 
successful in partially controlling viral replication. Indeed, viral load falls considerably 
(<0.5 log10) from an initial viral load of 106-107 copies of HIV RNA/mL of plasma within 
3-5 months of infection75. Immune activation remains high during chronic infection due 
to continuous stimulation of HIV-specific immune responses and can have delirious 
systemic effects including an increase risk of cancer, cardiovascular damage, and 
impaired liver and kidney function. Indeed, immune activation during chronic infection 
was found to correlate strongly with CD4+ T cell decline and progression to AIDS76-78. 
 
 During long-term cART, viremia drops below the clinical limit of detection, and it 
could be expected that immune activation would show a similar trend. However, in a 
subset of patients, immune activation remains high, even when suppression of viral 
replication has been achieved79. It is hypothesized that this could be due to several 
factors including translocation of microbial products from a gut damaged during acute 
infection into systemic circulation and chronic immune stimulation by residual viremia. A 
clinical trial evaluating the effects of rifaximin, an antibiotic that does not diffuse from the 
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gut, is underway to investigate microbial translocation as a cause of chronic 
inflammation. The role of residual viremia in chronic immune activation is discussed 
later in this report. 
 
 
 
 
2.4 – HIV VIREMIA IN UNTREATED PATIENTS AND THOSE ON SUPPRESSIVE ART  
 
 
 Viremia is the result of productive cycles of viral replication, resulting in the 
release of virions into blood. It should be noted that viremia is highly dynamic, in that the 
half life of free virus in blood is estimated to be approximately 8 hours80. During acute 
infection, viremia can reach over 1 X 106 copies of HIV RNA/mL of plasma. Following 
initiation of cART, viremia undergoes a multiphasic decay consisting of four distinct 
phases, each with a longer half-life than the previous. The first phase has a half-life of 
t1/2 = 1-2 days and is thought to be due to the rapid decay of free virus and productively 
infected CD4+ T lymphocytes80-82. The second phase has a half-life of t1/2 = 2-4 weeks 
and is due to the slower attrition of infected cells that are partially resistant to the 
cytopathic effects of HIV, such as macrophages or partially activated CD4+ T 
lymphocytes58,83. During the second phase of decay, viremia falls below the limit of 
clinical detection, and it was based on the trajectory of viremia, it was estimated that the 
virus could be cleared from the body in 2-3 years58. The discovery of resting CD4+ 
memory cells with a half-life of 44 months demonstrated that this estimate was far too 
optimistic59,61,62. The third phase, with a half life of t1/2 = 39 weeks, continues until 
viremia plateaus at approximately 1 copy/mL of plasma84 and remains unchanged for at 
least seven years (t1/2 = ∞)85. 
 
 The specific set-point to which viremia decays differs among individuals and is 
influenced by a number of factors. These include, (1) viral load prior to initiation of 
cART84,86, (2) the duration of time between infection and intiation of cART86-88, and (3) 
the length of time an individual is on suppressive ART89,90. Interestingly, the set-point of 
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residual viremia did not correlate with treatment regimen or CD4+ T lymphocyte count84. 
The correlation between residual viremia and immune activation are discussed below. 
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CHAPTER 3: SINGLE COPY ASSAYS OF PLASMA HIV-1 RNA 
 
 
 
 
3.1 – DEVELOPMENT AND METHODOLOGY OF THE PLASMA HIV-1 RNA SINGLE 
COPY ASSAY 
 
 
 The first single copy assay was developed at the National Cancer Institute in 
2003. By this time, combination antiretroviral therapy achieved durable suppression of 
plasma viremia such that in most patients, viral load fell below the lower limit of clinical 
sensitivity (generally 50 copies/mL plasma)84,91. Although a number of “home-brew” 
assays91 and modifications to Amplicor HIV Monitor test88,92,93 with varying sensitivities 
had been developed, they lacked single copy sensitivity and had not been formally 
validated for use among different research groups. Therefore, the advent of the plasma 
HIV-1 RNA single copy assay marked the first time residual viremia could be measured 
reliably with single copy sensitivity94. 
 
 The single copy assay utilizes a guanidinium isothiocynate-based extraction 
method to separate virion-associated HIV-1 RNA from plasma. Whole blood is first 
subjected to a low-speed centrifugation at 400 x g for 10 minutes at 4˚C to pellet cellular 
components. The plasma is removed subjected to a second, high-speed centrifugation 
at 1350 x g for 15 minutes at 4˚C to remove additional macromolecular complexes. 
Finally, the plasma is subjected to ultracentrifugation at 150,000 x g for 30 minutes to 
pellet HIV-1 virions. The supernatant is removed, and the pellet is incubated with 2.0 
mg/mL proteinase K at 56˚C for 30 minutes to digest the protein components of the 
virions. 6M guanidinium isothiocyanate supplemented with 0.2 mg of glycogen is then 
added, and the pellet is incubated for 10 minutes at room temperature to bring all virion 
components into suspension. Isopropanol is added, and the solution is centrifuged at 
21,000 x g for 30 minutes to pellet the nucleic acids. The resulting pellet is then washed 
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twice with 70% ethanol to remove the guanidinium salts, which would otherwise 
interfere with downstream PCR steps. 
 
 Once the pellet has been washed and dried, the nucleic acids are resuspended 
in 55 mL of 5 mM Tris-HCl supplemented with 1mM dithiothreitol and 1000 U of RNase 
inhibitor to stabilize the virion-associated HIV-1 RNA. The RNA is then reverse 
transcribed into cDNA in a one-to-one ratio by PCR.. Finally, HIV-1 cDNA is 
quantitatively amplified using primers and probes specific for conserved regions of the 
HIV-1 gag gene on a Roche Lightcycler platform (Fwd: 5’-CAT GTT TTC AGC ATT ATC 
AGA AGG A-3’; Rev: 5’-TGC TTG ATG TCC CCC CAC T-3’; Probe: 5’-FAM CCA CCC 
CAC AAG ATT TAA ACA CCA TGC TAA-TAMRA-3’). A triplicate semi-log dilution of 
HIV-1 RNA transcripts, ranging from 3-3,000 copies per well, is included with each run 
to serve as an internal standard curve. The lower limit of quantification, which is 
dependent on the total volume of plasma assayed, was 0.6 copies/mL for 3.0 mL of 
plasma. 
 
 
 
 
3.2 – VALIDATION OF THE PLASMA HIV-1 RNA SINGLE COPY ASSAY 
 
 
 Single copy assays require several forms of validation to ensure single-copy 
sensitivity is achieved and to establish consistency from run to run. The first is the 
preparation of HIV-1 RNA standards that serve as an external  standard curve and for 
endpoint dilution to determine assay sensitivity. The second is the use of a low copy 
number standard, which contains a consistent concentration of HIV-1 RNA. 
 
 
3.2.1 – Serial Dilution of HIV-1 RNA Transcripts 
 
 
 HIV-1 RNA transcripts are prepared by in vitro synthesis of gag HIV-1 RNA from 
a plasmid construct. Following synthesis, the RNA of known length is quantified by 
spectrophotometry, and the transcripts are serially diluted to 1 X 105  copies/mL, and 
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aliquots are stored at -80˚C. To validate that the concentration is accurate, the 
transcripts are further diluted to 1 copy/well and dilutions from 1-100 copies/well are 
amplified in replicates of 10. According to Poisson statistics, 95% of wells containing 3 
copies/well and 63% of wells containing 1 copy/well should be positive for HIV-1 RNA. If 
transcript amplification deviates from these expected results, the aliquots of HIV-1 RNA 
are prepared again until the expected results are achieved. 
 
 
3.2.2 – VQA 5 as a Positive Control 
 
 
 A plasma standard known to contain 5 copies of HIV-1 RNA/mL of plasma is 
included with each run to ensure accurate quantification of low copy number HIV-1 RNA 
in unknown samples. This standard is prepared off-site by the serial dilution of virion-
associated HIV-1 RNA from a viremic donor. The acceptable range for quantative 
amplification of this standard is from 2.5-7.5 copies/mL of plasma. 
 
 
 
 
3.3 – PRIOR USES OF THE PLASMA HIV-1 RNA SINGLE COPY ASSAY 
 
 
 The plasma single-copy assay has been used in extensively to quantify residual 
viremia for a number of purposes. The three most common applications have been (i) to 
assess the efficacy of treatment regimens, (ii) to determine whether treatment regimens 
can be simplified, and (iii) to quantify the impact of treatment intensification on residual 
viremia. In the second case, treatment simplification is desirable if fewer drugs can be 
used to maintain suppression of viremia. In the latter case, treatment intensification has 
been used to assess whether complete suppression of viremia has been achieved. 
 
 Several early studies focused on the efficacy of different treatment regimens at 
controlling viremia. The first report of this kind showed that tenofovir (TDF) was better 
than stavudine (d4T) when co-administered with efavirenz (EFV) and lamivudine 
(3TC)95. The mean post-treatment residual viremia was lower in the TDF arm (3.8 vs 4.1 
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copies/mL), and more patients had undetectable viremia (47% vs. 29%). In a later 
retrospective study, nevirapine (NVP) was found to be better than EFV in achieving 
undetectable viremia (81% vs. 56%) when used in combination with emtricitabine (FTC) 
and TDF96. However, this study did not utilize randomized groups. A larger, randomized 
trial of d4T, 3TC, and either nelfinavir or lopinavir/ritonavir showed residual viremia was 
no different between the two arms84. The last of these findings is consistent with 
complete suppression of residual viremia, regardless of treatment regimen. 
 
Treatment simplification is desirable to reduce medication cost, pill burden, drug 
toxicities, and drug-drug interactions. To this end, two studies have investigated 
reducing a standard combination therapy (typically two nucleoside reverse transcriptase 
inhibitors (NRTIs) and a ritonavir-boosted protease inhibitor) to a simplified regimen. In 
the first, 81% of patients (17 of 21) experienced no change in residual viremia when 
their regimen was simplified to ritonavir-boosted lopinavir97. Similarly, in the second 
study, 88% of patients (30 of 34) experienced no change in residual viremia when 
ritonavir-boosted atazanavir was administered in the absence of NRTIs98,99. Therefore, 
these studies suggest that viral suppression is maintained following treatment 
simplification in most patients. 
 
In contrast to treatment simplification, treatment intensification has been used to 
investigate whether complete viral suppression has been achieved by standard 
combination therapy. Several reports have studied the intensification effects of 
efavirenz, raltegravir (RAL), and ritonavir-boosted protease inhibitors on residual 
viremia and found no change in plasma HIV-1 RNA89,100-104. Interestingly, two RAL 
studies yielded results that indicate low-level HIV replication may continue despite no 
change in residual viremia100,104. The first showed a RAL-mediated increase in 2-LTR 
circles in circulating mononuclear cells following treatment intensification, which is 
indicative of recent infection events100. The second found an increase in cell-associated 
unspliced HIV-1 RNA in ileal tissue104. Neither of these studies has been reproduced, so 
further investigation is necessary to validate these findings. The most recent 
intensification studies have been performed using maraviroc (MVC), a viral entry 
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inhibitor105,106. Although one study found an increase in residual viremia105, others that 
examined larger cohorts were unable to reproduce these findings106,107. Overall, these 
studies indicate that current treatments likely achieve full suppression of replication. 
 
 
 
 
3.4 – FUTURE SINGLE COPY ASSAYS 
 
 
 Single copy assays capable of quantifying cell-associated HIV-1 nucleic acids 
are needed to obtain a more complete picture of HIV-1 dynamics during viral 
suppression. To this end, assays have been developed to quantify cell-associated HIV-
1 DNA (spliced + unspliced), 2-LTR circles DNA, and full length HIV-1 RNA. In order to 
begin with cells, these assays omit the proteinase K digestion, include several 
sonication steps, and in the case of cell-associated HIV-1 RNA, require DNA digestion. 
Otherwise, extraction of nucleic acids and quantitative amplification are the same as 
described in Section 3.1. 
 
 
 
 
3.5 – THESIS APPLICATIONS OF THE PLASMA HIV-1 SINGLE COPY ASSAY  
 
 
 The plasma HIV-1 single copy assay is used in two studies described in this 
report. The first investigates the effects of treatment intensification with MVC on residual 
viremia. The second examines whether residual viremia correlates with T cell activation 
in a study of the role of regulatory T cells in patients with virologic suppression. Neither 
study utilizes cell-associated HIV-1 single copy assays described in Section 3.4. 
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CHAPTER 4 – MEASUREMENT OF IMMUNE ACTIVATION 
 
 
 
 
4.1 – MARKERS OF IMMUNE ACTIVATION 
 
 
 Although many distinct markers have been used to characterize T cell activation, 
only CD38 and HLA-DR were considered in the studies described in this report. CD38, 
a cyclic ADP ribose hydrolase, is expressed on the surface of a variety of immune cells, 
but is frequently used as a marker of T cell activation. HLA-DR is a MHC Class II 
surface receptor that is up-regulated in response to T cell signaling, which results in T 
cell activation.  In contrast to CD38, HLA-DR is a late marker of activation, and is 
therefore expressed less frequently. In the context of these studies, activated T cells are 
defined as having a CD38+ HLA-DR+ phenotype. 
 
 
 
 
4.2 – FLOW CYTOMETRY APPLICATIONS 
 
 
 Flow cytometric analysis is to determine the frequency of CD4+ & CD8+ 
activated T cells. Briefly, peripheral blood mononuclear cells are isolated from blood by 
Ficoll-Paque density gradient separation. The resulting cells are stained with 
fluorochrome conjugated antibodies specific for CD4, CD8, CD38, and HLA-DR and 
fixed with 2% paraformaldehyde. The cells are analyzed using an LSR II with FACS 
Diva software along with positive, negative, and isotype controls within three days of 
staining. 
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CHAPTER 5 – RESIDUAL VIREMIA AND IMMUNE ACTIVATION I 
 
 
 
 
5.1 – DESCRIPTION OF A5256: MARAVIROC INTENSIFICATION STUDY 
 
 
 A5256 was designed as a multicenter, open-label, single-arm clinical trial in 
which 32 participants added MVC (Pfizer Inc.) to their existing suppressive ART 
regiment, were monitored for 24 weeks, then discontinued MVC and were monitored for 
an additional 24 weeks. MVC was administered orally twice a day with doses ranging 
from 150 mg to 600 mg depending on pharmacokinetic interactions with the patients’ 
pre-study medications as specified by the manufacturer. Additionally, patients were 
asked not to alter their ART regimens during intensification (i.e. week 0 – week 24). 
Patients who experience virologic failure, defined as two consecutive instances of 
detectable plasma HIV-1 RNA by the clinical assay used at the patient’s local site, 
discontinued MVC. 
 
 Patients underwent two baseline assessments prior to adding MVC to their ART 
regimens. Patients then provided blood samples at 4, 8, 12, 16, 22, and 24 weeks post-
entry (i.e. during intensification) and 36, 46, and 48 weeks post-entry (i.e. after 
intensification). HIV-1 RNA was quantified at weeks 12, 24, 36, and 48 by a CLIA-
certified laboratory using an FDA-approved HIV-1 RNA quantification assay (lower limit 
of detection of ≤75 copies/mL). 
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5.2 – PATIENT COHORT 
 
 
 Of the 61 patients screened for this study, 34 met the inclusion criteria and were 
enrolled (Table 1). These included 32 males (94%) including 24 white non-Hispanics 
(71%), 6 black non-Hispanics (18%), and 4 Hispanics (12%). Patients had a median 
age of 50 years (range: 41-64 years), a median baseline CD4 T cell count of 153 
cells/mL (range: 20-272 cells/mL), a median baseline CD8+ T cell count of 559 cells/mL 
(range: 20 – 1,365 cells/mL), and a median duration of clinically undetectable viremia of 
3.5 years (range: 1.0 – 12.6 years). 
  
 Of the 34 patients who enrolled, there were two (6%) who experienced virologic 
failures upon entry (i.e. at week 0) and stopped treatment intensification. One subject 
withdrew from the study at week 12, while the other remained in the study follow-up.  
One additional subject did not continue follow-up after week 22. There were 15 patients 
(44%) who experienced adverse events, of whom 7 (21%) experienced grade 3 events. 
The most frequently reported adverse events, aside from “other”, were hepatic, 
respiratory, and gastrointestinal in manifestation. No grade 4 events were experienced, 
and no events were severe enough to warrant discontinuation of MVC. 
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Table 1: Baseline Characteristics 
 
Characteristic Total Subjects (N=34) 
Age (years)  
     Median [Q1, Q3] 50 [47, 55] 
     Mean (standard deviation) 51 (6) 
     Min, Max 41, 64 
Sex   
     Male 32 (94%) 
     Female 2 (6%) 
Race/Ethnicity  
     White Non-Hispanic 24 (71%) 
     Black Non-Hispanic 6 (18%) 
     Hispanic (Regardless of Race) 4 (12%) 
Pre-Entry Nadir CD4 Count  
     ≤50 23 (68%) 
     51 – 100 9 (26%) 
     101 – 200 2 (6%) 
Pre-Entry CD4 Count Slope 
(cells/mm3/year)  
     Median [Q1, Q3] 5.81 [-14.02, 12.13] 
     Mean (standard deviation) 0.99 (12.75) 
     Min, Max -18.17, 18.05 
Baseline CD4 Count (cells/mm3) †  
     Median [Q1, Q3] 153 [119, 203] 
     Mean (standard deviation) 154 (61) 
     Min, Max 20, 272 
Years with Undetectable Plasma HIV-
1 RNA Prior to Entry ‡  
     Median [Q1, Q3] 2.95 [1.80, 4.50] 
     Mean (standard deviation) 3.54 (2.34) 
     Min, Max 1.00, 12.60 
 
† Baseline CD4 count was calculated as the mean of the last two measurements 
obtained prior to or at the start of MVC. 
‡ Four (4) subjects had no documentation or recall of the date when their plasma HIV-1 
RNA became undetectable 
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5.3 – CHANGES IN RESIDUAL VIREMIA BY STUDY WEEK 
 
 
 Despite clinically undetectable viremia, 11 patients (35%) had detectable plasma 
HIV-1 RNA by SCA with a median of 2.9 copies/mL (range: 1.2 – 11.0 copies/mL) at 
pre-entry (week -1). At entry (week 0) 10 patients (32%) had detectable plasma HIV-1 
RNA with a median of 2.4 copies/mL (range: 1.2 – 7.9 copies/mL).  When MVC was 
discontinued at week 24, 14 patients (48%) had detectable plasma viremia with a 
median of 3.9 copies/mL (range: 1.2 – 12.2 copies/mL). Although two patients 
experienced transient increases in plasma HIV-1 RNA during the intensification period, 
their viral loads returned to baseline before discontinuation of MVC at week 24. Overall, 
there was no consistent change in residual viremia during the intensification period or 
after discontinuation of MVC as shown in Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Change in low-level residual viremia among subjects (N=32) before, during 
and after MVC intensification (N=7 patients never had detectable residual viremia). The 
y-axis represents plasma HIV-1 RNA as determined by single copy assay, and the x-
axis reflects the study week. Intensification occurred between weeks 0 and 24. 
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5.4 – CORRELATION BETWEEN BASELINE T CELL ACTIVATINO AND BASELINE 
HIV-1 DNA 
 
 
 
 
 In addition to examining residual viremia during MVC intensification, we also 
investigated the relationship between T cell activation and total HIV-1 DNA in the CD4+ 
compartment at baseline. Regarding CD4+ T cells, the frequency of activation (i.e. HLA-
DR+ CD38+) was negatively correlated with baseline total HIV-1 DNA as shown in 
Figure 2.(Spearman correlation = -0.52; p = 0.004).However, a similar correlation was 
not observed between CD8+ T cell activation and total HIV-1 DNA at baseline as shown 
in Figure 3 (Spearman correlation = -0.14; p = 0.48). 
 
 
 
Figure 2: Negative correlation between CD4+ T cell activation and CD4+ cell HIV-1 
DNA among subjects (N=28) at baseline. The y-axis represents the percentage of CD4+ 
T cells with an activated phenotype (i.e. HLA-DR+, CD38+) as determined by flow 
	   21	  
cytometry. The x-axis reflects the number of copies of HIV-1 DNA detected per million 
CD4+ T cells as determined by quantitative amplification of HIV-1 DNA. Of note, no 
distinction was made between integrated and unintegrated HIV-1 DNA molecules. 
 
 
 
Figure 3: Correlation between CD8+ T cell activation and CD4+ cell HIV-1 DNA among 
subjects (N=28) at baseline. The y-axis represents the percentage of CD8+ T cells with 
an activated phenotype (i.e. HLA-DR+, CD38+) as determined by flow cytometry. The x-
axis reflects the number of copies of HIV-1 DNA detected per million CD4+ T cells as 
determined by quantitative amplification of HIV-1 DNA. Of note, no distinction was made 
between integrated and unintegrated HIV-1 DNA molecules. 
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CHAPTER 6 – RESIDUAL VIREMIA AND IMMUNE ACTIVATION II 
 
 
 
 
6.1 – STUDY DESCRIPTION 
 
 
 This study was part of the Male AIDS cohort study (MACS) and was approved by 
the University of Pittsburgh Institution Review board. The cohort consisted of HIV-1 
infected subjects (n=36) as well as age matched HIV-1 negative controls (NC; n=10). 
Specifically, the cohort consisted of treatment naïve patients (n=9) and patients on 
suppressive ART with CD4+ T cell counts of >500 cells/mm3 (ART500; n=15) and ≤350 
cells/mm3 (ART350; n=12). All subjects gave written informed consent and donated 20 
mL of blood from which plasma and PBMCs were isolated. 
6.2 – Correlations between Immune Activation, CD4+ Count, and Residual Viremia 
 
 The frequency of activated (i.e. CD38+/HLA-DR+) CD4+ and CD8+ T cells was 
significantly higher in untreated subjects and those with ≤350 cells/mm3 (ART300) than 
in normal controls or in patients with >500 cells/mm3 (ART500). This indicates that in 
the context of antiretroviral therapy, sub-optimal recovery of the CD4+ T cell 
compartment correlates with high immune activation. 
 
 Interestingly, there was no correlation between residual viremia and CD4+ or 
CD8+ T cell activation. This suggests that residual viremia does not drive chronic 
immune activation. 
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Figure 4: Correlation between CD4+ T cell count and the frequency of activated (A) 
CD4+ or (B) CD8+ T cells. Correlation between residual viremia and frequency of 
activated (C) CD4+ or (D) CD8 + T cells. (Courtesy of Bernard Macatangay) 
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CHAPTER 7 – SUMMARY AND DISCUSSION 
 
 
 
 
 The relationship between chronic immune activation and residual viremia in the 
context of suppressive antiretroviral therapy is controversial. Specifically, whether 
chronic immune activation is caused by residual viremia or simply correlates with it has 
been difficult to investigate in vivo. In this report, data from two studies show that 
chronic inflammation is independent of residual viremia. In the first study, reduced 
immune activation mediated by MVC, possibly due to immunosuppressive activity of 
MVC, was not accompanied by a reduction in residual viremia upon intensification of 
suppressive regimens with MVC. In the second study, the frequency of immune 
activation was not dependent on the level of plasma viremia. Together, these data 
continue to support a model in which chronic immune activation is driven by factors 
other than residual viremia during long-term antiretroviral therapy. 
 
 Immune activation and inflammation are widely associated with disease, and the 
correlation between immune activation and progression to AIDS in untreated HIV 
infection is now widely recognized78. Although immune activation peaks during acute 
infection, it was observed to decrease to a steady set-point during chronic infection; this 
set-point also represents an independent indicator of CD4+ T cell decline and 
progression to AIDS76,108. Therefore during chronic, untreated infection, a positive 
feedback loop between immune activation and viral replication is established. There are 
numerous consequences to this chronic inflammation including fibrosis of secondary 
lymphoid organs, impaired T cell function, microbial translocation via damaged gut 
mucosa, and irreparable attrition of the memory T cell compartment. The most striking 
in vivo evidence supporting the causal relationship between immune activation and 
disease comes from primate studies of SIV109. Although SIV replicates quite well in old 
world monkeys, immune activation and disease progression remains low. 
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 Upon initiation of antiretroviral therapy, HIV replication is suppressed and 
immune activation is reduced due to a lack of antigenic stimulation. Despite the paucity 
of virus in the blood, immune activation fails to normalize in a many patients and 
remains high79. These patients suffer from many of the same ailments seen in untreated 
infection and are at increased risks of non-AIDS defining illnesses such as 
cardiovascular, liver, kidney, and neurological diseases, as well as cancer. The reasons 
for chronic immune activation are unclear, but may include (1) antigenic stimulation by 
residual viremia, (2) microbial translocation through damaged gut mucosa110, and (3) 
incomplete reconstitution of the CD4+ T cell compartment. Therefore, it is critical to 
determine the causes of chronic immune activation in order to better control 
inflammation-associated diseases. 
 
 In the A5256 study, the role of antigenic stimulation in response to residual 
viremia was addressed. To date, no study has conclusively demonstrates that 
intensification of existing suppressive ART regimens further reduces residual viremia. 
These include studies that have examined NNRTIs101, PIs101, integrase 
inhibitors89,102,103, and MVC106,107. Our data is in agreement with these reports in that we 
found no durable reduction in residual viremia. Interestingly, immune activation was 
reduced during intensification and was partially reversed when MVC administration 
ceased. These results are consistent with several studies that have reported MVC-
induced reductions in immune activation. A study by Funderburg et al. (n=57) compared 
the effects of MVC and efavirenz on markers of immune activation in treatment naïve 
patients111; the levels of CD4+CD38+ cells, D-dimer, and CRP in peripheral blood were 
all found to decrease during MVC intensification. Similarly, a report by Vitrello et al. 
(n=20) demonstrated MVC-dependent reduction in soluble CD30 (a marker of T cell 
activation) in patients on suppressive ART112. Lastly, a study by Wilkin et al. (n=34) 
showed the frequencies of CD4+ T cells expressing markers of immune activation 
(CD38+ and CD38+/HLA-DR+) and proliferation (Ki67+) decreased during MVC 
intensification, and increased following cessation of MVC107. These studies (and ours) 
differ from a report by Hunt et al. (n=45), who described an increase in CD38+HLA-DR+ 
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in peripheral CD8+ T cells after 24 weeks of MVC intensification113; moreover, this study 
found the frequencies of CD4+ and CD8+ T cells expressing CD38 and HLA-DR nearly 
doubled in rectal tissue. Interestingly, this study also reported a decrease in soluble 
LPS, but an increase in soluble CD14. The reasons for the disparities between these 
results are unclear, but may be related to unrecognized difference in patient cohorts or 
specific methods used to quantify fluctuations in markers of immune activation. 
 
 Although residual viremia did not correlate with immune activation, analysis of 
baseline data revealed an inverse correlation between CD4+ T cell activation and total 
HIV-1 DNA in the CD4+ T cell compartment (rho = -0.52; p = 0.004). In contrast, a 
recent study by Hatano et al. on a large cohort of treated subjects (n = 109) found a 
modest positive correlation between CD4+ T cell activation and proviral HIV-1 DNA (rho 
= 0.16; p = 0.057)114. This is also true of an earlier study investigating correlations 
between CD8+ T cell activation and viral “blips.” In theory, elevated CD4+ T cell 
activation may drive HIV expression by fostering a environment conducing to 
intracellular HIV-1 RNA expression. This could result in cell death, either through 
cytopathic effects of viral proteins or through cytotoxic responses by innate and 
adaptive immune cells. Since this process would lead to attrition of proviruses capable 
of expressing HIV-1 RNA, it would be reflected as relatively low levels of total HIV DNA 
in the CD4+ T cell compartment. 
 
 In addition to the role of residual viremia driving immune activation, the 
relationship between CD4+ T cell count and immune activation was also examined. 
Untreated patients and those on ART with sub-optimal T cell recovery (ART350) 
exhibited high levels of immune activation compared to patients with appreciable T cell 
recovery (ART500) and healthy controls. Since CD4+ T cells are critical to coordinating 
the adaptive immune response against HIV, low T cell counts compromise the ability of 
the adaptive immune system to respond to infections. Although residual viremia does 
not appear influence immune activation, other antigenic stimulation from microbial 
translocation, co-infections (hepatitis B and C), and pathogens that are typically well 
controlled in healthy individuals (e.g. CMV & EBV) are potential causes. Further studies 
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utilizing techniques to perturb these different parameters while monitoring changes in 
immune activation are required to fully elucidate the factors that contribute to chronic 
immune activation.  
 
 Although informative, these studies have several limitations that must be 
acknowledged. First, the MVC study was a single-arm trial without a control group, so 
small effects on residual viremia as well as variables other than MVC intensification 
cannot be addressed. Second, only one primer/probe set specific for a conserved 
region of the HIV-1 genome was used to assay residual viremia. At most, 48% of 
patients had detectable residual viremia, and it is possible that primer/probe 
mismatches resulted in false negatives. For both studies, pre-therapy samples were not 
available, so no plasma remains to test this hypothesis. Finally, these studies did not 
consider ongoing replication in anatomical sites not reflected in the blood, such as the 
gastrointestinal tract, genital tract, and central nervous system. It is conceivable that 
limited, ongoing replication occurs in these sites and helps drive chronic immune 
activation 
 
 Despite the limitations, these data contribute to our knowledge of chronic 
immune activation and its relationship to residual viremia and CD4+ T cell count. The 
absence of changes to residual viremia during MVC intensification strongly supports 
existing evidence that (1) residual viremia does not originating from ongoing cycles of 
HIV-1 replication, and (2) residual viremia does not drive immune activation. This is 
further supported by the lack of correlation between immune activation and residual 
viremia in the second study. Although MVC may have utility in treating individuals with 
drug resistance mutations against first-line therapies, it may be useful in blunting 
immune activation in patients on suppressive ART, as well as in other maladies driven 
by immune activation; indeed, MVC has been shown to have utility in the context of 
graft versus host disease115. Our study attempted to help discern the relationship 
between residual viremia and immune activation. We found  no relationship between 
these parameters, and the concept that immune activation drives residual viremia was 
not supported. 
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